Juxtapid (lomitapide) is a microsomal triglyceride transfer protein inhibitor specifically indicated for the treatment of homozygous familial hypercholesterolemia (HoFH). As a potent lipid-lowering drug, its use must strictly follow the principles of dose adjustment, and individualized medication management should be implemented for different patient populations.
Dosage and Administration, Recommended Dosage of Juxtapid (Lomitapide)
Initial Dose and Maintenance Dose
The recommended starting dose of lomitapide is 5 mg orally once daily.
The dose should be gradually increased based on the patient’s safety and tolerability.
After at least 2 weeks, the dose can be increased to 10 mg daily. Then, with an interval of at least 4 weeks, increase the dose to 20 mg, 40 mg in sequence, and finally reach the maximum recommended dose of 60 mg daily.
Standardized Administration Method
This product should be taken on an empty stomach at least 2 hours after the evening meal. It should be swallowed whole with water in the form of intact capsules; do not open, crush, dissolve, or chew the capsules.
Strictly adhering to the required administration time is crucial for reducing the risk of gastrointestinal adverse reactions.
Essential Nutritional Supplementation
Lomitapide reduces the absorption of fat-soluble vitamins and fatty acids.
Patients need to supplement 400 international units of vitamin E daily, as well as at least 200 mg of linoleic acid, 210 mg of alpha-linolenic acid (ALA), 110 mg of eicosapentaenoic acid (EPA), and 80 mg of docosahexaenoic acid (DHA).
Dose Adjustment of Juxtapid (Lomitapide)
Adjustment Based on Liver Enzyme Levels
When alanine aminotransferase (ALT) or aspartate aminotransferase (AST) reaches 3 times the upper limit of normal (ULN) but less than 5 times the ULN, it is recommended to recheck and confirm within one week.
If the elevation is confirmed, reduce the dose and obtain other liver function-related test indicators.
Management of Significant Elevation of Liver Enzymes
If ALT or AST is ≥ 5 times the ULN, discontinue the medication, immediately conduct a comprehensive liver function test, and investigate potential causes.
If the elevation of transaminases is accompanied by clinical symptoms of liver injury (such as nausea, vomiting, abdominal pain, fever, jaundice, drowsiness, or flu-like symptoms), bilirubin ≥ 2 times the ULN, or active liver disease, discontinue lomitapide immediately and conduct a comprehensive investigation of the cause.
Medication for Special Populations with Juxtapid (Lomitapide)
Medication for Patients with Liver Impairment
The daily dose for patients with mild liver impairment (Child-Pugh Class A) should not exceed 40 mg.
This product is contraindicated in patients with moderate to severe liver impairment (Child-Pugh Class B or C) or active liver disease.
Medication for Patients with Renal Impairment
The daily dose for patients with end-stage renal disease receiving dialysis should not exceed 40 mg.
Data on medication use in patients with other degrees of renal impairment are insufficient.
Medication for Elderly Patients
Clinical studies of lomitapide did not include a sufficient number of patients aged 65 years and above.
Therefore, medication use in this population should be cautious, and factors such as decreased liver and renal function, as well as concurrent medications, should be considered.
Pregnant and Lactating Women
This product is contraindicated in pregnant women, as it may cause fetal harm.
Women of childbearing potential should undergo a pregnancy test before starting treatment, and the result must be negative. Effective contraceptive measures should be taken during treatment.
Lactating women should make a choice between taking the medication and breastfeeding.
